Compare Ascendis Pharma A/S (ASND) vs Icl Group Ltd (ICL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Icl Group Ltd — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Icl Group Ltd trades at $4.87 (market cap $6.30B). The key difference: Ascendis Pharma A/S is far larger — about 2.8× Icl Group Ltd's market cap, and Icl Group Ltd pays a 3.93% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | ICL | |
|---|---|---|
Market Cap | $17.74B | $6.30B |
Sector | Health | Basic Materials |
52-Week High | $277.18 | $7.07 |
52-Week Low | $163.32 | $4.80 |
Enterprise Value | $18.11B | $8.87B |
Dividend Yield | — | 3.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
ICL trades at $4.85, unchanged on the day, with a bearish technical signal from moving averages. The company reported Q1 2026 earnings of $0.11 per share, beating expectations, and recently completed an $800 million senior notes offering. Revenue for 2025 was $7.15 billion, with a net income margin of 3.52% and a P/E ratio of 23.1. Analyst consensus is entirely Hold, with no Buy or Sell ratings among the four covering firms.
ICL faces headwinds from declining profit margins and elevated raw material costs, but operational improvements and raised 2026 EBITDA guidance offer some upside. Key risks include geopolitical tensions and foreign exchange volatility. The stock's current valuation appears fair, with limited near-term catalysts given the neutral analyst sentiment and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
